Our Board
Lung Cancer Europe is led by an Executive Board made up of the President, Vice-President, Treasurer and board members, all elected by the General Assembly. Board members serve voluntarily and are unpaid. The board sets our strategic direction and safeguards the organisation.
Debra Montague
PresidentDebra is the first President of Lung Cancer Europe with lived experience of lung cancer. For more than 25 years she worked in senior roles in the pharmaceutical industry, until a stage IV ALK-positive diagnosis in 2016 changed her path: she founded ALK Positive Lung Cancer UK, the leading charity for people with ALK+ in the UK, and joined the board of ALK Positive Europe. She was elected Vice-President of Lung Cancer Europe in 2023 and President in 2025.
Angeliki Souri
Vice PresidentAngeliki became Vice-President of Lung Cancer Europe in 2025, having joined the board in 2024. She built a 20-year career in communications and sales, and as a graduate of the University of Athens in Political Science and Public Administration she now works as a translator and editor. She represents FairLife Lung Cancer Care, Greece’s first non-profit dedicated to lung cancer, where she leads on content and communications.
Soumitra Böse
TreasurerSoumitra became Treasurer of Lung Cancer Europe in April 2026, bringing financial stewardship and governance insight to the board. After a career in finance, he has spent more than a decade as a trustee and treasurer of NGOs and community organisations in India and the UK. Diagnosed with stage 2 EGFR-positive lung cancer in 2021, he is an EGFR Positive Lung Cancer UK trustee, focusing on awareness, support, and the governance that keeps a charity sustainable.
Merel Hennink
Board MemberMerel joined the board of Lung Cancer Europe in 2025, representing the Dutch organisation Longkanker Nederland. She moved from a career in programme management and teaching at Hanze University of Applied Sciences into full-time advocacy after a stage IV ROS1-positive diagnosis in 2014, founding Stichting Merels Wereld to raise awareness of ROS1 and drive research. That work helped launch a ROS1 research programme with Hanze University and University Hospital Groningen.
Nicoline Ehrhardt
Board MemberNicoline joined the board of Lung Cancer Europe in 2025. She is the Founder and Chair of ALK Positive Europe, a non-profit network connecting lung cancer organisations and advocates across Europe in support of people affected by ALK-positive lung cancer, and brings extensive experience in lung cancer advocacy to the board.
Strategy and direction
Set the strategic direction so Lung Cancer Europe delivers its vision and mission
Make sure the organisation is meeting its mission, objectives and purpose
Keep the organisation developing effectively and in line with its statutes
Decide which projects to take on and which congresses to attend, and follow them up
People and oversight
Oversee contractors so the organisation runs smoothly
and projects land on time
Recruit, support and, where necessary, release staff
Monitor staff performance and the quality of their work
Appoint a board member to oversee staff against an agreed plan and report back
Maintain effective working practices, with a clear division of roles between board and staff
Ensure a suitable succession plan is in place
Legal and financial responsibility
Hold legal and financial responsibility, with systems in place to protect and grow the organisation
Put the right policies and practices in place for sound governance and administration
Secure and manage the funding the organisation needs
Review and approve the budget before the Annual General Meeting (AGM), and ensure funds are used as agreed
Keep accounts as required by law and good practice
Members and representation
Review and approve membership applications
Manage membership, including ending it, as set out in the Constitution
Act as ambassadors, representing Lung Cancer Europe rather than their home organisation
Promote and uphold the organisation's values: representativeness, commitment, reliability, trust and uniqueness